Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

NCT03824392 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Sarcoidosis

Interventions

BIOLOGICAL: Efzofitimod 1.0 mg/kg or Placebo
BIOLOGICAL: Efzofitimod 3.0 mg/kg or Placebo
BIOLOGICAL: Efzofitimod 5.0 mg/kg or Placebo

Sponsor

aTyr Pharma, Inc.

Collaborators

[object Object]